IL6 and cancer: IL-6 can potentially influence anti-PD-L1 efficacy through several mechanisms, including support of cancer cell fitness,2,4 inhibition of Th1 responses,5,8,10 promotion of immunosuppressive myeloid cells,7,9,40,41,42 or disruption of conventional dendritic cells (cDCs).43